MDNAFOTCPharmaceutical PreparationsFiscal year ends March 31
Medicenna Therapeutics Corp.
Financials through fiscal 2023, year ended Mar 31, 2023Last filing: 20-F on Jun 27, 2023
$0.28−0.02 (-7.63%)
Close on Oct 19, 2026
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2023
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
5 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2019 | FY2023 | Trend |
|---|---|---|---|---|
| Current ratio | – | – | 9.57 | |
| Diluted shares | – | – | 65M |
Cash use needs five years of cash flow figures
Medicenna Therapeutics does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2023 against fiscal 2022
1of 2 tests passed in fiscal 2023. Some tests lack the figures they need.
- ProfitableNet income above zero–
- Cash generatingOperating cash flow above zero–
- Return on assets improvedROA up on the prior year– → –
- Earnings backed by cashOperating cash flow above net income– vs –
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose8.92 → 9.57
- No dilutionShare count did not rise54M → 65M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –